4-29-2008

Clinical Guidelines for Diagnosis and Management of Asthma

Maine Department of Health and Human Services
Maine Center for Disease Control and Prevention

Follow this and additional works at: https://digitalmaine.com/mecdc_docs

Recommended Citation
Maine Department of Health and Human Services and Maine Center for Disease Control and Prevention, "Clinical Guidelines for Diagnosis and Management of Asthma" (2008). Center for Disease Control Documents. 87.
https://digitalmaine.com/mecdc_docs/87

This Text is brought to you for free and open access by the Health & Human Services at Digital Maine. It has been accepted for inclusion in Center for Disease Control Documents by an authorized administrator of Digital Maine. For more information, please contact statedocs@maine.gov.
Asthma Management for Children and Adults

Consider the diagnosis of “asthma” if:

1. **RECURRENT** coughing, wheezing, or shortness of breath relieved by a bronchodilator
2. Objective response by spirometry (≥12% increase of FEV₁ post bronchodilator)
3. Rule out conditions such as aspiration, GERD, airway anomaly, foreign body, cystic fibrosis, vocal cord dysfunction, or COPD. GERD is a common co-morbidity. (If diagnosis in doubt, consult with an asthma specialist.)

**Environmental Control**: identify and avoid triggers such as tobacco smoke, pollens, molds, animal dander, cockroaches, and dust mites.

**Flu Vaccine**: recommend annually.

**Spirometry**: at diagnosis and at least annually.

**Asthma Score**: use tools such as ACQ®, ACT™ or ATAQ© to assess asthma control.

**Asthma Education**: review correct inhaled medication device technique every visit, if needed.

**Asthma Action Plan**: at diagnosis; review and update at each visit.

**Short-Acting Beta-Agonist** (e.g., albuterol):
1) for quick relief every 4-6 hours as needed (see step 1),
2) pretreat with 2 puffs for exercise-induced bronchospasm 10-60 minutes before exercise.

**Oral Corticosteroids**: consider for acute exacerbation.

**Spacer with Valve**: if spacer selected, use spacer with valve.

**Mask**: use with spacer with valve and with nebulizer for children <5 years and anyone unable to use correct mouthpiece technique.

See www.coloradoguidelines.org for additional asthma management resources.

**Consider referral to a specialist if not well controlled within 3-6 months using stepwise approach OR 2 or more ED visits or hospitalizations for asthma in a year.**

Adapted from the NAEPP 3: http://www.nhlbi.nih.gov/guidelines/asthma/. This guideline is designed to assist the clinician in the management of asthma. This guideline is not intended to replace the clinician’s judgment or establish a protocol for all patients with a particular condition. For references, additional copies of the guideline, or patient documents go to www.coloradoguidelines.org or call (720) 297-1681 or 866-401-2092. This publication was supported by cooperative agreement #2U59EH024177-04 Revised, from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. This Guideline was originally developed by Colorado Clinical Guidelines Collaborative.
Asthma
Stepwise Approach

Intermittent Asthma

Step 1 (all ages)
Short-acting beta-agonist (e.g., albuterol prn)
If used more than 2 days per week (other than for exercise) consider inadequate control and the need to step up treatment.

Step 2
All Ages
Preferred: Low-dose inhaled steroid
Alternative: Leukotriene blocker or cromolyn

Step 3
Age 12 yrs
Preferred: Low-dose inhaled steroid + long-acting beta-agonist or Medium-dose inhaled steroid
Alternative: Medium-dose inhaled steroid + leukotriene blocker

Step 4
Age 12 yrs
Preferred: Medium-dose inhaled steroid + long-acting beta-agonist
- and -
Consider omaluzimab if allergies

Step 5
Age 12 yrs
Preferred: High-dose inhaled steroid + long-acting beta-agonist + oral steroid
- and -
Consider omaluzimab if allergies

Step 6
Age 12 yrs
High-dose inhaled steroid + long-acting beta-agonist + oral steroid + omaluzimab if allergies

Step 1
Age 0-4 yrs
Consider referral (especially if diagnosis is in doubt)

Age 0-4 yrs
Medium-dose inhaled steroid + referral

Age 0-4 yrs
Medium-dose inhaled steroid + long-acting beta-agonist or leukotriene blocker or Medium-dose inhaled steroid

Age 0-4 yrs
Medium-dose inhaled steroid + either long-acting beta-agonist or leukotriene blocker

Age 0-4 yrs
High-dose inhaled steroid + either long-acting beta-agonist or leukotriene blocker + oral steroid

All ages Steps 4 through 6: Consult with asthma specialist

Persistent Asthma: Daily Medication

Step up as indicated although address possible poor adherence to medication. Re-assess in 2 to 6 weeks.

Step down if well controlled and re-assess in 3 months. If very stable then assess control every 3 to 6 months.

All LABAs and combination agents containing LABAs have a black box warning.

Adapted from the NAEPP 5: http://www.nhlbi.nih.gov/guidelines/asthma/ This guideline is designed to assist the clinician in the management of asthma. This guideline is not intended to replace the clinician’s judgment or establish a protocol for all patients with a particular condition. For references, additional copies of the guideline, or patient documents go to www.coloradoguidelines.org or call (720) 297-1681 or 866-401-2902. This publication was supported by cooperative agreement 2U59EH82417-04 Revised, from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. This Guideline was originally developed by Colorado Clinical Guidelines Collaborative. Revised 04/29/08